Case Reports in Medicine

Case Reports in Medicine / 2016 / Article

Case Report | Open Access

Volume 2016 |Article ID 3212947 |

Susumu Takamatsu, Kota Sato, Shunsuke Kato, Hiroto Nagano, Shunro Ohtsukasa, Yasuyuki Kawachi, "Splenic Involvement in Hereditary Hemorrhagic Telangiectasia", Case Reports in Medicine, vol. 2016, Article ID 3212947, 4 pages, 2016.

Splenic Involvement in Hereditary Hemorrhagic Telangiectasia

Academic Editor: Michael Hünerbein
Received19 Jul 2016
Accepted22 Sep 2016
Published11 Oct 2016


A 33-year-old man who presented with prolonged epigastric pain was referred to our hospital. He had experienced recurrent epistaxis and had a family history of hereditary hemorrhagic telangiectasia. Computed tomography and magnetic resonance imaging revealed splenomegaly and a 9 cm hypervascular mass in his spleen. Computed tomography also showed a pulmonary arteriovenous malformation and heterogeneous enhancement of the liver parenchyma, suggesting the presence of arteriosystemic shunts and telangiectases. Based on these findings, the patient was definitely diagnosed with hereditary hemorrhagic telangiectasia according to Curaçao criteria. He underwent splenectomy, and his symptoms disappeared after surgery. Pathological examination of the resected specimen revealed that the hypervascular lesion of the spleen was not a tumor but was composed of abnormal vessels associated with hereditary hemorrhagic telangiectasia. Symptomatic splenic involvement may be a rare manifestation of hereditary hemorrhagic telangiectasia but can be revealed by imaging modalities.

1. Introduction

Hereditary hemorrhagic telangiectasia (HHT; Rendu-Osler-Weber syndrome) is an autosomal dominantly inherited disorder with a prevalence of 1 in 10000 to 1 in 5000 individuals [1]. HHT is characterized by the presence of vascular abnormalities, such as telangiectases and/or arteriovenous malformations (AVMs), in the lungs, brain, gastrointestinal tract, liver, and spinal cord [2]. However, the spleen is rarely affected.

This report described a patient with HHT, who underwent splenectomy for a hypervascular lesion of the spleen; pathologic examination of the resected specimen confirmed splenic involvement in HHT.

2. Case Presentation

A 33-year-old man who presented with prolonged epigastric pain was referred to our hospital. Outpatient laboratory data were within normal limits, except that his serum carbohydrate antigen 19-9 concentration was slightly elevated, to 79.8 U/mL (normal range 0–36.99 U/mL). Physical examination showed no abnormal findings in the abdomen and no mucocutaneous telangiectases. Based on a personal history of recurrent spontaneous epistaxis and pulmonary AVM and a positive family history, in that his mother has been diagnosed with HHT, this patient had been diagnosed with HHT according to Curaçao criteria [3]. Abdominal enhanced computed tomography (CT) showed a 9 cm hypervascular mass in his enlarged spleen (Figure 1). CT also demonstrated a pulmonary AVM and both transient perfusion abnormalities and a large confluent vascular mass [4] of the liver (Figure 2). Furthermore, arterial phase of enhanced CT showed three major hepatic veins. Both CT and enhanced magnetic resonance imaging (MRI) strongly suggested that the hypervascular splenic lesion was a tumor. Brain MRI, however, showed no evidence of cerebrovascular malformations.

The patient underwent splenectomy based on a diagnosis of a symptomatic hypervascular tumor of the spleen. Macroscopic examination of the resected specimen, however, revealed no evidence of a splenic tumor (Figure 3). Rather, pathological examination showed the presence of hemorrhage and hemosiderosis in the area thought to be a hypervascular tumor on CT and MRI. Moreover, the vessels in that area appeared telangiectatic and thin walled, with intimal hyperplasia (Figure 4). These results suggested that the hypervascular lesion in this patient was splenic involvement in HHT. The postoperative course of this patient was uneventful, and he was discharged from the hospital on postoperative day 5. After surgery, his abdominal pain disappeared and he has remained asymptomatic. Genetic testing was not performed.

3. Discussion

HHT, also known as Rendu-Osler-Weber syndrome, is a relatively uncommon, autosomal dominant inherited disorder [1]. The abnormal vascular structures in HHT were found to result from mutations in the transforming growth factor-ß/bone morphogenetic protein signaling pathway genes endoglin [5, 6] and activin type-II-like receptor kinase 1 [7]. Clinically, the organs most frequently affected by HHT are the lungs, brain, liver, and gastrointestinal tract [2]. Splenic involvement is considered a rare manifestation, with only a few case reports describing splenic involvement in patients with HHT [810].

Although several studies have described the CT findings associated with hepatic involvement in HHT [4, 11], this involvement is not well understood. Retrospectively, CT demonstrated hepatic involvement in the present patient but was unable to show hepatic involvement preoperatively. Moreover, preoperative CT was unable to diagnose the hypervascular lesion of the spleen as splenic involvement of HHT. To our knowledge, no studies to date have fully described splenic characteristics on imaging modalities in patients with HHT, making it difficult to associate specific findings of the spleen with splenic involvement in HHT.

Most previously described HHT patients with visceral involvement have been asymptomatic [3]. Because splenic involvement in this patient was symptomatic, a surgical procedure was deemed necessary. A more precise preoperative diagnosis may have allowed laparoscopic splenectomy, which is regarded as safer and more preferable. The findings in this patient suggest the need to suspect splenic involvement in patients with HHT and to determine imaging characteristics diagnostic of this involvement.

In conclusion, HHT is a relatively uncommon disease, with splenic involvement being an especially rare manifestation. Splenic involvement in HHT should be included in the differential diagnoses of patients with hypervascular lesions of the spleen.

The patient has provided permission to publish the features of his case.


None of the authors are affiliated with or have financial involvement in any organization or entity with a direct financial involvement in the subject matter or materials of the research discussed in the paper.

Competing Interests

All authors declare that there is no conflict of interests regarding the publication of this article.


  1. U. W. Geisthoff, H.-L. Nguyen, A. Röth, and U. Seyfert, “How to manage patients with hereditary haemorrhagic telangiectasia,” British Journal of Haematology, vol. 171, no. 4, pp. 443–452, 2015. View at: Publisher Site | Google Scholar
  2. A. E. Guttmacher, D. A. Marchuk, and R. I. White Jr., “Hereditary hemorrhagic telangiectasia,” The New England Journal of Medicine, vol. 333, no. 14, pp. 918–924, 1995. View at: Publisher Site | Google Scholar
  3. C. L. Shovlin, A. E. Guttmacher, E. Buscarini et al., “Diagnostic criteria for Hereditary Hemorrhagic Telangiectasia (Rendu- Osler-Weber Syndrome),” American Journal of Medical Genetics, vol. 91, no. 1, pp. 66–67, 2000. View at: Publisher Site | Google Scholar
  4. A. A. S. Ianora, M. Memeo, C. Sabbà, A. Cirulli, A. Rotondo, and G. Angelelli, “Hereditary hemorrhagic telangiectasia: multi-detector row helical CT assessment of hepatic involvement,” Radiology, vol. 230, no. 1, pp. 250–259, 2004. View at: Publisher Site | Google Scholar
  5. K. A. McAllister, K. M. Grogg, D. W. Johnson et al., “Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1,” Nature Genetics, vol. 8, no. 4, pp. 345–351, 1994. View at: Publisher Site | Google Scholar
  6. C. L. Shovlin, “Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment,” Blood Reviews, vol. 24, no. 6, pp. 203–219, 2010. View at: Publisher Site | Google Scholar
  7. D. W. Johnson, J. N. Berg, C. J. Gallione et al., “A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12,” Genome Research, vol. 5, no. 1, pp. 21–28, 1995. View at: Publisher Site | Google Scholar
  8. J. Willis, M. J. Mayo, T. E. Rogers, and W. Chen, “Hereditary haemorrhagic telangiectasia involving the bone marrow and liver,” British Journal of Haematology, vol. 145, no. 2, p. 150, 2009. View at: Publisher Site | Google Scholar
  9. A. Notoya, T. Bohgaki, M. Mukai, M. Kohno, H. Sato, and K. Sawada, “Splenomegaly and chronic disseminated intravascular coagulation in Osler-Weber-Rendu disease: a case report,” American Journal of Hematology, vol. 65, no. 4, pp. 315–318, 2000. View at: Publisher Site | Google Scholar
  10. B. J. Folz, A. C. Wollstein, H. Alfke et al., “The value of screening for multiple arterio-venous malformations in hereditary hemorrhagic telangiectasia: a diagnostic study,” European Archives of Oto-Rhino-Laryngology, vol. 261, no. 9, pp. 509–516, 2004. View at: Publisher Site | Google Scholar
  11. M. Memeo, A. A. Stabile Ianora, A. Scardapane, P. Buonamico, C. Sabbà, and G. Angelelli, “Hepatic involvement in hereditary hemorrhagic telangiectasia: CT findings,” Abdominal Imaging, vol. 29, no. 2, pp. 211–220, 2004. View at: Publisher Site | Google Scholar

Copyright © 2016 Susumu Takamatsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.